Whole blood bactericidal activity during treatment of pulmonary tuberculosis

Robert S. Wallis, Solange A. Vinhas, John L. Johnson, Fabíola C. Ribeiro, Moisés Palaci, Renata L. Peres, Ricardo T. Sá, Reynaldo Dietze, Allan Chiunda, Kathleen Eisenach, Jerrold J. Ellner

Research output: Contribution to journalArticlepeer-review


The timely evaluation of new drugs that can be used to shorten tuberculosis (TB) treatment will require surrogate markers for relapse. This study examined bactericidal activity against intracellular Mycobacterium tuberculosis in whole blood culture (whole blood bactericidal activity; WBA) during TB treatment. In the absence of chemotherapy, immune mechanisms in patient blood resulted in bacteriostasis, whereas administration of oral chemotherapy resulted in bacillary killing. Total WBA per dose was greater during the intensive phase of treatment than during the continuation phase (mean, -2.32 vs. -1.67 log10 cfu-days, respectively; P10 cfu-days; P = .04) and correlated with the rate of decrease of sputum colony-forming unit counts during the first 4 weeks of treatment (P=.018), both of which are indicative of prognosis. These findings indicate that measurement of WBA may have a role in assessing the sterilizing activity of new anti-TB drugs.

Original languageEnglish (US)
Pages (from-to)270-278
Number of pages9
JournalJournal of Infectious Diseases
Issue number2
StatePublished - Jan 15 2003
Externally publishedYes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Fingerprint Dive into the research topics of 'Whole blood bactericidal activity during treatment of pulmonary tuberculosis'. Together they form a unique fingerprint.

Cite this